<DOC>
	<DOCNO>NCT01301001</DOCNO>
	<brief_summary>The Specific aim project ( 1 ) test prediction pain tampon insertion ( primary outcome measure ) low PVD patient treat gabapentin compare treated placebo . Secondary outcome measure include intercourse pain 24-hour pain ( 2 ) perform mechanism-based analysis gabapentin effectiveness , gain insight underlie pathophysiology subtypes PVD may lead specific treatment option .</brief_summary>
	<brief_title>A Trial Gabapentin Vulvodynia : Biological Correlates Response</brief_title>
	<detailed_description>This 18-week , randomize , double-blind , placebo-controlled , two-treatment , two-period crossover design , 120 woman 18 age old report insertional dyspareunia , pain tampon insertion , tenderness localize vulvar vestibule enrol study . Electronically enter daily diary use determine pain low PVD subject treat gabapentin ( 3600 mg/d ) compare treated placebo . Biological measurement include assessment allodynia hyperalgesia capsaicin administration , muscle tension use vaginal pressure algometer , number tender point clinical examination , change blood pressure , pulse heart rate variability . . The Long-range goal project explicate underlie pathophysiologic mechanism PVD , use knowledge create evidence-based differential diagnosis subtypes PVD individualize treatment subtype . The immediate goal conduct multicenter , randomize control trial ( RCT ) gabapentin treatment PVD , also provide critical data new PVD-testing response paradigm , well characteristic may define subtypes PVD . Gabapentin , anticonvulsant analgesic , anxiolytic , antispasmotic effect , select efficacy treat neuropathic pain condition .</detailed_description>
	<mesh_term>Vulvodynia</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>1 . Women 18 year age old , long vaginal atrophy present . If vaginal atrophy present , topical hormone replacement provide minimum 6 week must rescreened eligible , 2 . Greater 3 continuous month insertional ( entryway ) dyspareunia , pain touch , tampon insertion ( modify 'Friedrich 's Criteria ' , 3. average pain level `` 4 '' great 11point tampon test ( 0 = pain ; 10 = bad pain ever ) 2week screening period must exhibit . ( One tampon insert week ) . 4 . ) Must report pain `` Tampon Insertion Pain '' Test visit 1 1 . Other vulvar condition , include dermatosis , vulvitis , vulvar papillomatosis , atrophic vaginitis ( presence maturation index ) 2. previous vestibulectomy 3. active vaginal infection ( positive Affirm ™ VPIII microbial identification test ) 4. pregnancy risk pregnancy use reliable birth control method least 3 month prior enter study 5. unstable medical condition , include renal impairment ( creatinine clearance ≤60 mL/min , BUN &gt; 30mg/dL , serum creatinine &gt; 2 mg/dL ) , significant hematological disease ( leukopenia [ WBC &lt; 3.0 x 103µl , leukocytosis [ WBC &gt; 20.0 x 103μl ] , neutropenia [ ABS &lt; 1.50 x 103 μl , &lt; 20 % ] ) , ( thrombocytopenia [ platelet &lt; 100,000 μl ] , anemia [ HCT &lt; 27 % , HBG &lt; 8 g/dL , RBC &lt; 3 x 106 ] ) , cardiovascular disease ( cardiac conduction disturbance , CHF , hypertension [ 140/90 ] ) , hepatic insufficiency ( serum AST , ALT , ALP ≥ 3 time upper limit normal ) , neurological disorder ( seizure , syncopal episode , peripheral neuropathy , severe pain cause vulvodynia ) , autoimmune disease , respiratory illness 6. psychiatric disorder , include history major depressive disorder substance abuse disorder within past 6 month , score &gt; 12 depression subscale Hospital Anxiety Depression Scale ( HADS ) , indict major depressive episode ( 35,36 ) , serious risk suicide , lifetime history psychosis , hypomania mania 7. multiple allergy 8. use benzodiazepine , opiate , muscle relaxant , tricyclic antidepressant ( TCAs ) , serotoninnorepinephrine reuptake inhibitor ( SNRIs ) CNS stimulant ( include methylphenidate , amphetamine dextroamphetamine ) within 2 week randomization study 9. use certain herbal agent within 2 week randomization study , include ginkgo biloba , even primrose , St. John 's Wort , Valerian , kava kava ) 10. topical lidocaine use 11 . Subjects , diagnose coexist vaginismus , fibromyalgia and/or interstitial cystitis , must great vulvar pain coexist condition eligible study participation 12 . Subject previously take gabapentin Lyrica discontinue medication due side effect eligible 13 . Subjects active infection ( Candida , BV , trichomonas , chlamydia , GC HSV via Affirm/culture ) must treat rescreened eligible participation 14 . Subjects 10 % great parabasal cell and/or vaginal atrophy provide topical hormone replacement minimum 6 week must rescreened eligible 15 . Subjects gastric bypass surgery ineligible study participation due drug absorption problem 16 . HPV/abnormal Pap exclusionary 17 . Ongoing counsel and/or physical therapy exclusionary 18 . Subjects report sign mixed Vulvodynia ( spontaneous/provoked , localize , generalize ) prescreening exclude</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Vulvodynia</keyword>
</DOC>